Article Text
Abstract
The globular glial tauopathies (GGTs) are a rare group of neurodegenerative diseases with fewer than 90 autopsy-confirmed cases reported in the literature. Although there has been some uncertainty about whether GGT is entirely distinct from progressive supranuclear palsy, a recent study of tau filament structures supports the definition of GGT as a separate neuropathological entity. We present a sporadic case of GGT type II presenting with a progressive corticobasal–primary lateral sclerosis overlap syndrome in a 74-year-old woman. Neuropathological examination identified neuronal and glial tau inclusions, including globular astrocytic and oligodendroglial inclusions. We also discuss the clinical features and molecular pathophysiology of GGT. Increased awareness of this condition could become more important as patients with GGT may be candidates for anti-tau therapies currently undergoing clinical evaluation in patients with other tauopathies.
- NEUROPATHOLOGY
Data availability statement
Data sharing not applicable as no datasets generated and/or analysed for this study.
Statistics from Altmetric.com
Data availability statement
Data sharing not applicable as no datasets generated and/or analysed for this study.
Footnotes
Contributors PWC and TR drafted the manuscript and KS, KPB and TTW revised the manuscript and provided important intellectual content.
Funding PWC is supported by funding from the Reta Lila Weston Trust for Medical Research.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed by Richard Davenport, Edinburgh, UK.
Read the full text or download the PDF:
Other content recommended for you
- Molecular pathology of neurodegenerative diseases: principles and practice
- Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review
- Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease
- Neuropathology and emerging biomarkers in corticobasal syndrome
- Fluid biomarkers in frontotemporal dementia: past, present and future
- Therapeutic trial design for frontotemporal dementia and related disorders
- Predictors of survival in frontotemporal lobar degeneration syndromes
- [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia
- Neuronal network disintegration: common pathways linking neurodegenerative diseases
- TDP-43 proteinopathies: a new wave of neurodegenerative diseases